Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Lonimecgene renparvovec
3 evidence topics · 3 sources
Immunoprophylaxis schedule and taper in the trial protocols
Vaccination required before the immunosuppression regimen
Pre-existing anti-AAV9 antibodies in the nonclinical studies
“Serum AAV9 neutralizing (nAb) antibodies, were assessed before treatment. Animals with detectable nAbs (e.g., titers ≥1:10) were preferentially chosen for diluent-only treatment, whereas those with low or undetectable nAbs could receive rAAV9 treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical pharmacokinetic drug interaction studies
No evidence found.